On March 26, 2020, the Board of Directors of Lumos Pharma, Inc. appointed the Company’s current Chief Executive Officer, Rick Hawkins, to the additional role of President of the Company and Chairman of the Board, effective immediately. From and after March 26, 2020, Mr. Hawkins holds the titles of President and Chief Executive Officer and Chairman of the Board. Mr. Hawkins, age 71, has served as the Chief Executive Officer of the Company since March 18, 2020. Mr. Hawkins has also served as the President and Chief Executive Officer of Lumos Pharma Sub, Inc. (formerly “Lumos Pharma, Inc.”) since January 2011, and previously served as a member of the board of Lumos Pharma Sub, Inc. from January 2011 to March 2020. In addition, Mr. Hawkins currently serves on the board of directors of several life sciences companies, including Cytori Therapeutics, Inc., now known as Plus Therapeutics, Inc. and Savara Inc., and previously served on the board of directors of SciClone Pharmaceuticals, Inc. until its acquisition in October 2017. From 2000 to 2010, Mr. Hawkins, founded and advised numerous pharmaceutical companies including Sensus Drug Development Corporation, where he served as co-founder and Chairman until it was sold to Pfizer. From 1981 to 2000, Mr. Hawkins was founder, President and CEO of Pharmaco. The company later merged with PPD of Wilmington, NC to form PPD Pharmaco Inc. On March 23, 2020, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 30, 2019, by and among the Company, Cyclone Merger Sub, Inc., and Lumos Pharma Sub, Inc. (formerly Lumos Pharma, Inc.), as amended, the Board appointed Joe McCracken as a Class I director of the Company and as a member of the Audit Committee of the Board, effective immediately. Mr. McCracken will receive standard compensation and equity available to non-employee directors of the Company. Mr. McCracken will enter into the Company’s standard form of indemnification agreement with the Company, the form of which was filed as Exhibit 10.11 to the Company’s Amendment No. 6 to the Registration Statement on Form S-1 filed on November 8, 2011.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
LUMOS PHARMA, INC. 
